Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved..
The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread rapidly to become globally dominant and has split into a number of sublineages. BA.1 dominated the initial wave but has been replaced by BA.2 in many countries. Recent sequencing from South Africa's Gauteng region uncovered two new sublineages, BA.4 and BA.5, which are taking over locally, driving a new wave. BA.4 and BA.5 contain identical spike sequences, and although closely related to BA.2, they contain further mutations in the receptor-binding domain of their spikes. Here, we study the neutralization of BA.4/5 using a range of vaccine and naturally immune serum and panels of monoclonal antibodies. BA.4/5 shows reduced neutralization by the serum from individuals vaccinated with triple doses of AstraZeneca or Pfizer vaccine compared with BA.1 and BA.2. Furthermore, using the serum from BA.1 vaccine breakthrough infections, there are, likewise, significant reductions in the neutralization of BA.4/5, raising the possibility of repeat Omicron infections.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:185 |
|---|---|
| Enthalten in: |
Cell - 185(2022), 14 vom: 07. Juli, Seite 2422-2433.e13 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tuekprakhon, Aekkachai [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.07.2022 Date Revised 20.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cell.2022.06.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342932381 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342932381 | ||
| 003 | DE-627 | ||
| 005 | 20240320232754.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cell.2022.06.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM342932381 | ||
| 035 | |a (NLM)35772405 | ||
| 035 | |a (PII)S0092-8674(22)00710-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tuekprakhon, Aekkachai |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.07.2022 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread rapidly to become globally dominant and has split into a number of sublineages. BA.1 dominated the initial wave but has been replaced by BA.2 in many countries. Recent sequencing from South Africa's Gauteng region uncovered two new sublineages, BA.4 and BA.5, which are taking over locally, driving a new wave. BA.4 and BA.5 contain identical spike sequences, and although closely related to BA.2, they contain further mutations in the receptor-binding domain of their spikes. Here, we study the neutralization of BA.4/5 using a range of vaccine and naturally immune serum and panels of monoclonal antibodies. BA.4/5 shows reduced neutralization by the serum from individuals vaccinated with triple doses of AstraZeneca or Pfizer vaccine compared with BA.1 and BA.2. Furthermore, using the serum from BA.1 vaccine breakthrough infections, there are, likewise, significant reductions in the neutralization of BA.4/5, raising the possibility of repeat Omicron infections | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a BA.4 | |
| 650 | 4 | |a BA.5 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Omicron | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a VoC | |
| 650 | 4 | |a antibody escape | |
| 650 | 4 | |a variant | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 700 | 1 | |a Nutalai, Rungtiwa |e verfasserin |4 aut | |
| 700 | 1 | |a Dijokaite-Guraliuc, Aiste |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Daming |e verfasserin |4 aut | |
| 700 | 1 | |a Ginn, Helen M |e verfasserin |4 aut | |
| 700 | 1 | |a Selvaraj, Muneeswaran |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Chang |e verfasserin |4 aut | |
| 700 | 1 | |a Mentzer, Alexander J |e verfasserin |4 aut | |
| 700 | 1 | |a Supasa, Piyada |e verfasserin |4 aut | |
| 700 | 1 | |a Duyvesteyn, Helen M E |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Raksha |e verfasserin |4 aut | |
| 700 | 1 | |a Skelly, Donal |e verfasserin |4 aut | |
| 700 | 1 | |a Ritter, Thomas G |e verfasserin |4 aut | |
| 700 | 1 | |a Amini, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Bibi, Sagida |e verfasserin |4 aut | |
| 700 | 1 | |a Adele, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Sile Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Constantinides, Bede |e verfasserin |4 aut | |
| 700 | 1 | |a Webster, Hermione |e verfasserin |4 aut | |
| 700 | 1 | |a Temperton, Nigel |e verfasserin |4 aut | |
| 700 | 1 | |a Klenerman, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Barnes, Eleanor |e verfasserin |4 aut | |
| 700 | 1 | |a Dunachie, Susanna J |e verfasserin |4 aut | |
| 700 | 1 | |a Crook, Derrick |e verfasserin |4 aut | |
| 700 | 1 | |a Pollard, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Lambe, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Goulder, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Paterson, Neil G |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Mark A |e verfasserin |4 aut | |
| 700 | 1 | |a Hall, David R |e verfasserin |4 aut | |
| 700 | 0 | |a OPTIC Consortium |e verfasserin |4 aut | |
| 700 | 0 | |a ISARIC4C Consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Fry, Elizabeth E |e verfasserin |4 aut | |
| 700 | 1 | |a Huo, Jiandong |e verfasserin |4 aut | |
| 700 | 1 | |a Mongkolsapaya, Juthathip |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Jingshan |e verfasserin |4 aut | |
| 700 | 1 | |a Stuart, David I |e verfasserin |4 aut | |
| 700 | 1 | |a Screaton, Gavin R |e verfasserin |4 aut | |
| 700 | 1 | |a Conlon, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Deeks, Alexandra |e investigator |4 oth | |
| 700 | 1 | |a Frater, John |e investigator |4 oth | |
| 700 | 1 | |a Frending, Lisa |e investigator |4 oth | |
| 700 | 1 | |a Gardiner, Siobhan |e investigator |4 oth | |
| 700 | 1 | |a Jämsén, Anni |e investigator |4 oth | |
| 700 | 1 | |a Jeffery, Katie |e investigator |4 oth | |
| 700 | 1 | |a Malone, Tom |e investigator |4 oth | |
| 700 | 1 | |a Phillips, Eloise |e investigator |4 oth | |
| 700 | 1 | |a Rothwell, Lucy |e investigator |4 oth | |
| 700 | 1 | |a Stafford, Lizzie |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Cell |d 1974 |g 185(2022), 14 vom: 07. Juli, Seite 2422-2433.e13 |w (DE-627)NLM000088935 |x 1097-4172 |7 nnns |
| 773 | 1 | 8 | |g volume:185 |g year:2022 |g number:14 |g day:07 |g month:07 |g pages:2422-2433.e13 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cell.2022.06.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 185 |j 2022 |e 14 |b 07 |c 07 |h 2422-2433.e13 | ||